This study is in progress, not accepting new patients
N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan
a study on Neuroblastoma
Summary
- Eligibility
- for people ages 2-30 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- Katherine Matthay
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Katherine Matthay
Dr. Katherine Matthay is the chief of Pediatric Hematology-Oncology at UCSF Benioff Children's Hospital and has been focused for more than 20 years on translational research in neuroblastoma, a deadly childhood cancer. At UCSF, she has developed and led multiple trials using a unique targeted radiopharmaceutical, 131I-MIBG for neuroblastoma.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
- ID
- NCT02030964
- Phase
- Phase 1
- Study Type
- Interventional
- Last Updated